What does a partner check before licensing or sourcing biotech material?
Answer
They check the development stage and the data supporting it, the intellectual property position, and whether manufacturing can scale. Biotech partnering is an evidence and rights question, so stage-appropriate disclosure matters more than breadth of claim.
A business development team is assessing whether a programme is real enough and protected enough to justify a partnering conversation.
Information to make clear
Use the fields that affect this buying decision. Leave unsupported claims out.
- Technology platform and application
- What the technology does and where it applies.
- Development stage
- Research, preclinical, clinical or commercial changes everything.
- Intellectual property position
- Patents granted, pending and their territories.
- Manufacturing capability and scale
- Whether the product can be made at commercial scale.
- Regulatory pathway
- The route and stage in each target market.
- Quality systems in place
- Determines readiness for regulated work.
- Partnering model sought
- Licensing, supply, co-development or acquisition.
Documents to prepare
State what can be published, shared on request or issued with an order.
| Document | What it supports | Suggested handling |
|---|---|---|
| Intellectual property summaryMay be requested at: partnering discussion: the core asset | Patent families, status and territories | Share on request |
| Development stage data packageMay be requested at: due diligence | The evidence supporting the current stage | Share on request |
| Quality certificationMay be requested at: partner assessment | Quality systems appropriate to the development stage | Publish |
| Manufacturing capability statementMay be requested at: commercial assessment | Scale achieved and scale achievable | Share on request |
| Regulatory correspondence summaryMay be requested at: due diligence | Interactions and agreed pathway with authorities | Share on request |
| Publication and peer review recordMay be requested at: credibility assessment | Independently reviewed evidence for the platform | Publish |
| Material transfer and confidentiality termsMay be requested at: before any exchange | How material and data are shared before a deal | Publish |
Details to ask in an enquiry
Collect only the information needed to assess the request and respond.
- Technology and application of interest
- Determines the fit.
- Partnering model sought
- Licensing, supply or co-development.
- Development stage required
- Partners have stage preferences.
- Territory and rights of interest
- Defines the deal shape.
- Technical due diligence needs
- What evidence will be required.
- Timeline and decision process
- Partnering timelines are long.
Related questions
How much should a biotech company publish publicly?
Enough for a partner to determine fit and credibility: the platform, the application, the development stage, the publication record and the partnering model sought. The data package belongs behind confidentiality, but a site that says nothing specific cannot start a conversation either.
How should development stage be described?
Precisely and conservatively, using the standard terminology for the field. Partners assess risk by stage, and precision is read as competence. Ambiguity intended to make a programme look more advanced is detected quickly and remembered.
What role does the publication record play?
It is often the strongest public credibility signal available, because it is independently reviewed. Listing peer-reviewed publications lets a partner assess the science before contact, which is exactly what they want to do first.
This is an editorial checklist, not a compliance standard. Requirements vary by market, customer and contract. Confirm current requirements with the responsible technical and commercial teams.
Plact Research. Plact's editorial desk for buyer-evidence guides. The guides organize common buyer questions, documents and enquiry fields. Requirements should be checked against current standards, regulations and contracts.